Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients

Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients

BackgroundIntravenous 0.9 mg/kg recombinant tissue plasminogen activator (r-tPA) is one of the most effective treatments in acute ischemic stroke patients. Practically, the dose of r-tPA is still a topic that is constantly being discussed.MethodsFor this observational study, data were obtained from...

Full description

Bibliographic Details
Main Authors: Jiawen Yuan, Ruxing Wu, Jingyan Xiang, Jiangshan Deng, Xiaojie Zhang, Kaili Lu, Fengya Cao, Fei Zhao, Yuwu Zhao, Feng Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Neurology
Subjects:
acute ischemic stroke
intravenous thrombolysis
r-tPA
dose
sub-group analyses
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.1007167/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.1007167/full

Similar Items